Cancer Genetics, Inc. Receives New York State Approval for Focus::CLL™, a Unique NGS Panel for Chronic Lymphocytic Leukemia, Reinforcing the Company’s Market-Leading Position in the Diagnosis and Management of B-Cell Cancers

Focus::CLL™ is the only CLIA-validated and NYS-approved NGS panel for CLL that offers information for patient risk stratification, disease management, and treatment selectionFocus::CLL™ addresses a significant market of over 120,000 patients in the US living with CLL,...